Skip to main content

Table 4 Multivariate analysis of correlation between angptl3 and HDL components in the study subjects

From: Different relationship between ANGPTL3 and HDL components in female non-diabetic subjects and type-2 diabetic patients

Controls vs. T2DM

Female controls

Female T2DM

Male controls

Male T2DM

Estimate (95 % CI)

Estimate (95 % CI)

Estimate (95 % CI)

Estimate (95 % CI)p

N in category

149

150

149

150

HDL components

 Cholesterol (mg/dL)

2.57 (0.48 to 4.65)*

1.69 (0.13 to 3.25)*

2.07 (0.14 to 4.00)*

4.36 (2.08 to 6.64)Å‚

 ApoA-I (μg/mL)

1.14 (0.88 to 1.40)§

1.25 (0.87 to 1.63)§

−0.03 (−0.42, 0.36)

0.38 (−0.02 to 0.78)

 Serum amyloid A(μg/L)

−47.07 (−89.60 to −4.53)*

−11.7 (−43.15 to 66.57)

−14.19 (−53.93 to 25.56)

−6.16 (−50.99 to 38.66)

 Triglyceride (log, mg/dL)

1.00 (0.93 to 1.08)

1.00 (0.93 to 1.07)

1.03 (0.97 to 1.09)

1.12 (1.04 to 1.20)*

 Phospholipid (pg/mL)

−5.96 (−74.81 to 62.89)

−37.24 (−91.14 to 16.66)

−54.71 (−127.59 to 18.18)

83.09 (15.18 to 151.00)*

 Sphingosine-1-phosphate (nmol/L)

−14.33 (−88.89 to 60.24)

−124.3 (−0.64 to 249.30)

−28.02 (−106.40 to 50.37)

16.94 (−84.79 to 118.67)

  1. All associations were adjusted for age, body mass index and lipid lowering drugs (Statins and Niacin). Estimates given with 95 % CI express the difference in HDL components associated with 1-SD increase of ANGPTL3
  2. Significance: § p < 0.0001; ł p < 0.01; * p < 0.05